29 results match your criteria: "Spain J.G.-F.; Complejo Hospitalario de Navarra[Affiliation]"
Ventricular Tachycardia and Early Fibrillation in Patients With Brugada Syndrome and Ischemic Cardiomyopathy Show Predictable Frequency-Phase Properties on the Precordial ECG Consistent With the Respective Arrhythmogenic Substrate.
Circ Arrhythm Electrophysiol
October 2015
From the Arrhythmia Unit, Hospital Universitario Central de Asturias, Oviedo, Spain (D.C., J.R.); Center for Arrhythmia Research, University of Michigan, Ann Arbor (J.J., O.B.); Arrhythmia Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain (F.A., P.Á., Á.A.); Centro de Investigación e Innovación en Bioingeniería, Ci2B, Universitat Politècnica de Valencia, Valencia, Spain (J.S., L.M., A.F.); Arrhythmia Unit, Hospital Río Hortega de Valladolid and Universitario de Burgos, Valladolid-Burgos, Spain (B.H., J.G.-F.); Universitat de Valencia, Valencia, Spain (R.S.); and Department of Statistics, Hospital Universitario Central de Asturias, Oviedo, Spain (P.M.-C.).
Background: Ventricular fibrillation (VF) has been proposed to be maintained by localized high-frequency sources. We tested whether spectral-phase analysis of the precordial ECG enabled identification of periodic activation patterns generated by such sources.
Methods And Results: Precordial ECGs were recorded from 15 ischemic cardiomyopathy and 15 Brugada syndrome (type 1 ECG) patients during induced VF and analyzed in the frequency-phase domain.
Doppler-derived intracoronary physiology indices predict the occurrence of microvascular injury and microvascular perfusion deficits after angiographically successful primary percutaneous coronary intervention.
Circ Cardiovasc Interv
March 2015
From the Departments of Cardiology (P.F.A.T., G.A.d.W., M.R.H., L.F.H.J.R., I.D., P.S.B., R.P.A., R.N., C.P.A., J.S.L., Y.E.A., K.M.M., J.G.F.B., A.C.v.R., A.M.B., P.K., N.v.R.), Epidemiology and Biostatistics (M.W.H.), Radiology and Nuclear Medicine (A.A.L., P.G.R.), and Molecular Cell Biology and Immunology (A.J.G.H.), VU University Medical Center, Amsterdam, The Netherlands; and Cardiovascular Institute, Hospital Clinico San Carlos/Complutense University, Madrid, Spain (M.E.-P., A.Q., C.B., J.E.).
Background: A total of 40% to 50% of patients with ST-segment-elevation myocardial infarction develop microvascular injury (MVI) despite angiographically successful primary percutaneous coronary intervention (PCI). We investigated whether hyperemic microvascular resistance (HMR) immediately after angiographically successful PCI predicts MVI at cardiovascular magnetic resonance and reduced myocardial blood flow at positron emission tomography (PET).
Methods And Results: Sixty patients with ST-segment-elevation myocardial infarction were included in this prospective study.
Selected CD133⁺ progenitor cells to promote angiogenesis in patients with refractory angina: final results of the PROGENITOR randomized trial.
Circ Res
November 2014
From the Cardiology and Hematology Department, Hospital Clínico San Carlos, IdISSC, Madrid, Spain (P.J.-Q., J.J.G.-F., L.L., E.B., A.O.-P., R.H.-A., F.A., N.G., J.E., C.B., A.F.-O., B.D.N., M.d.T., E.G., C.M.); Cardiology and Hematology Department, Hospital Clinic, IDIBAPS, Barcelona, Spain (M.S., A.R., P.M.); Cardiology Department, Hospital Sant Pau, Barcelona, Spain (X.G.-M.); Department of Radiology and Nuclear Medicine, San Pedro Hospital and Centre for Biomedical Research of La Rioja (CIBIR), Logroño (La Rioja), Spain, and Institute Focuscan, Madrid, Spain (R.D.-B.); Statistic Department, Hospital Clínico San Carlos, Madrid, Spain (C.F.); and Pharmacology Department, Complutense University, Madrid, Spain (T.T., S.R.).
Article Synopsis
- Refractory angina is a significant clinical issue, and this study aimed to evaluate the safety and feasibility of injecting CD133(+) cells to promote blood vessel growth in affected patients.
- In a randomized, double-blind trial involving 28 patients, the results showed safety for the cell injections, with some adverse events but no major differences in overall effectiveness between treatment and control groups.
- However, patients who received the CD133(+) cell treatment experienced a notable reduction in monthly angina episodes and improved heart function as indicated by SPECT imaging, suggesting potential for further research into this therapy.
A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool.
Neuro Oncol
April 2014
Instituto Biodonostia and Hospital Universitario Donostia, San Sebastian, Spain (L.M., N.S., C.B., I.R., A.M., A.L.-M.); Center for Applied Medical Research (CIMA), Pamplona, Spain (E.G., V.S.); Clínica Universidad de Navarra, Pamplona, Spain (J.G.P-L., M.G-H., P.J., S.T., R.D.-V., J.R., A.G., E.X., M.M.A.); Polymat, University of the Basque Country, San Sebastian, Spain (A.A.); IMMA-CIOCC, Fundación Hospital de Madrid, Madrid, Spain (A.A.); Fundación Jimenez-Díaz, Madrid, Spain (J.G.-F.); Complejo Hospitalario de Navarra, Pamplona, Spain (T.T., I.Z.); Pitié-Salpètriere, Paris, France (S.P., J.Y.D.).
Background: Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults, and its prognosis remains dismal despite intensive research and therapeutic advances. Diagnostic biomarkers would be clinically meaningful to allow for early detection of the tumor and for those cases in which surgery is contraindicated or biopsy results are inconclusive. Recent findings show that GBM cells release microvesicles that contain a select subset of cellular proteins and RNA.
View Article and Find Full Text PDF